Lipocine Inc.

NASDAQ
LPCN
paper.types.company
Rentabilité sur six mois: -11%
Rendement en dividendes: 0%
Secteur: Healthcare

Calendrier des promotions Lipocine Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Lipocine Inc.

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis.

plus de détails
It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2013-10-22
ISIN
US53630X1046
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 2.22 7
P/BV 1.18 9
P/E 2973.6 1
Efficacité
Nom Signification Grade
ROA 0.0367 1
ROE 0.0404 1
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.0154 10
Debt/Ratio 0.000763 10
Debt/Equity 0.0721 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % -30.45 0
Rentabilité Ebitda, % -93.78 0
Rentabilité EPS, % -100.02 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 3.12 $ 0 $ 0 $ -0.01 % 0 % 0 %
common.calendar.number_days.7d 3.3 $ 3.12 $ 3.3 $ -5.61 % 0 % 0 %
common.calendar.number_days.30d 3.58 $ 3.12 $ 3.69 $ -12.99 % 0 % 0 %
common.calendar.number_days.90d 3.07 $ 2.83 $ 3.99 $ 1.47 % 0 % 0 %
common.calendar.number_days.180d 3.5 $ 2.83 $ 5.29 $ -11 % 0 % 0 %
common.calendar.number_days.1y 3.7 $ 2.83 $ 9.3 $ -15.81 % 0 % 0 %
common.calendar.number_days.3y 10.31 $ 0.32 $ 82.36 $ -69.79 % 0 % 0 %
common.calendar.number_days.5y 1.85 $ 0.32 $ 82.36 $ 68.38 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.32 $ 82.36 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 3.63 $ 2.83 $ 5.29 $ -14.19 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Mahesh V. Patel Ph.D. Co-Founder, Interim Principal Financial Officer, Director, President & CEO 762.53k 1957 (68 années)
Ms. Krista Fogarty Principal Accounting Officer & Corporate Controller 321.07k 1968 (57 années)
Dr. Nachiappan Chidambaram Ph.D. Senior Vice President of Research & Development 385.71k 1969 (56 années)
Mr. Logan Morse Vice President of Sales, Marketing & Operations 413.58k 1970 (55 années)
Dr. Anthony DelConte M. D., M.D. Chief Medical Director 1958 (67 années)

Informations sur l'entreprise

Adresse: United States, Salt Lake City. UT, 675 Arapeen Drive - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.lipocine.com